Impact of COVID-19 on Quality of Life for Seniors with Eye Diseases
Impact of COVID-19 on Quality of Life of Seniors With Eye Disease and Implementations to Improve Wellness
This study looks at how the COVID-19 pandemic has impacted the quality of life for seniors over 65 with eye diseases to see what challenges they faced during this time.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 425 (estimated) |
| Ages | 65 Years and up |
| Sex | All |
| Sponsor | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's Academic / other |
| Locations | 1 site (London, Ontario) |
| Trial ID | NCT04910282 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess how the COVID-19 pandemic has affected the quality of life of seniors aged 65 and above who have eye diseases such as glaucoma, age-related macular degeneration, or diabetic retinopathy. It will collect data from 425 patients through online questionnaires that evaluate health-related quality of life, vision-related quality of life, and symptoms of depression. The study seeks to understand the psychological stressors faced by these patients due to delays in treatment and the risk of infection during healthcare visits. The findings could inform strategies to improve patient wellness during and after the pandemic.
Who should consider this trial
Good fit: Ideal candidates for this study are seniors aged 65 and above who have been diagnosed with an eye disease by an ophthalmologist.
Not a fit: Patients who are unable to provide informed consent or have significant mental health disorders may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved management strategies for elderly patients with eye diseases during health crises, enhancing their overall quality of life.
How similar studies have performed: While the impact of COVID-19 on various patient populations has been studied, this specific focus on seniors with eye diseases is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients diagnosed with an eye disease by an experienced ophthalmologist. * Patients with eye diseases age 65 and above. * Be able to provide valid informed consent to participate in the research study. * Being able to read and understand English. * Having no significant self-reported or a physician diagnosed mental health disorder. Exclusion Criteria: * Inability to provide a valid informed consent. * Significant communication barriers or lack of English proficiency that prevents participants from completing the questionnaires. * Severe depression as confirmed by a CES-D ≥ 24. * Having a lifetime diagnosis of self-reported other serious mental disorders, including bipolar I or II disorder, primary psychotic disorder (schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder). * Self-reported substance abuse or dependence within the past 3 months. * Having an acutely unstable medical illnesses, including delirium or acute cerebrovascular or cardiovascular events within the last 6 months. * Having irreversible vision loss that prevents one from completing the questionnaires.
Where this trial is running
London, Ontario
- St. Joseph's Hospital — London, Ontario, Canada (Recruiting)
Study contacts
- Principal investigator: Monali Malvankar — Western University, Canada
- Study coordinator: Monali M Malvankar, PhD
- Email: monali.malvankar@sjhc.london.on.ca
- Phone: 5196858500
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.